Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.52 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | AHR | P35869 | 2/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.37 |
| ▸ | PNMT | P11086 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | PKLR | P30613 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30543420 | 0.88 | PARP1 (0.41) | PARP1NOTUMAHRADRA2AADRA2B | |
| SCHEMBL15319473 | 0.88 | PARP1 (0.41) | PARP1NOTUMAHRADRA2AADRA2B | |
| SCHEMBL31170845 | 0.75 | HTR2C (0.48) | PNMTHTR2C | |
| SCHEMBL9817774 | 0.74 | AHR (0.39) | PARP1NOTUMAHRADRA2AADRA2B | |
| SCHEMBL13651166 | 0.74 | PARP1 (0.52) | PARP1ADRA1AADRA1DADRA1BHTR2C | |
| SCHEMBL293877 | 0.74 | PARP1 (0.52) | PARP1ADRA1AADRA1DADRA1BHTR2C | |
| SCHEMBL16127651 | 0.74 | PARP1 (0.52) | PARP1ADRA1AADRA1DADRA1BHTR2C | |
| SCHEMBL13635655 | 0.74 | PARP1 (0.52) | PARP1ADRA2AADRA1AADRA1DADRA1B | |
| SCHEMBL5542419 | 0.74 | PARP1 (0.56) | PARP1HTR2CIDH1SLC6A2SLC6A4 | |
| SCHEMBL30363808 | 0.74 | PARP1 (0.52) | PARP1ADRA1AADRA1DADRA1BHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3130583-B1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION INC (US) | 2024-01-03 | — | — | EP | disclosed |
| US-10442782-B2 | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-10442782-B2 | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2019-10-15 | — | — | US | disclosed |
| EP-3049389-B1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION INC (US) | 2019-08-07 | — | — | EP | disclosed |
| EP-3049389-B1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION INC (US) | 2019-08-07 | — | — | EP | disclosed |
| US-20190047977-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | EVOTEC (UK) LTD. (GB) | 2019-02-14 | — | — | US | disclosed |
| US-20190047977-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | EVOTEC (UK) LTD. (GB) | 2019-02-14 | — | — | US | disclosed |
| US-20180222838-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2018-08-09 | — | — | US | disclosed |
| US-20180222838-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2018-08-09 | — | — | US | disclosed |
| US-20180222838-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2018-08-09 | — | — | US | disclosed |
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-28 | — | — | US | disclosed |
| US-7985762-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-26 | — | — | US | disclosed |
| US-20110165120-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-07 | — | — | US | disclosed |
| US-7964624-B1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-21 | — | — | US | disclosed |
| US-20070179167-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
| EP-1126836-B1 | BENZAMIDE POTASSIUM CHANNEL INHIBITORS | MERCK & CO INC (US) | 2007-02-14 | — | — | EP | disclosed |
| EP-1126836-A4 | BENZAMIDE POTASSIUM CHANNEL INHIBITORS | MERCK & CO INC (US) | 2002-09-04 | — | — | EP | disclosed |
| EP-1126836-A1 | BENZAMIDE POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2001-08-29 | — | — | EP | disclosed |
| US-6194458-B1 | 1-(2-METHOXYPHENYL)-1-OXO-2-AZA-(S)-4-I-BUTYL-4-PHENYLBUTANE, FOR EXAMPLE; TREATING VARIOUS CONDITIONS INCLUDING TRANSPLANTATION REJECTION OF ORGANS OR TISSUES IN A PATIENT; IMMUNOSUPPRESSANT COMPOSITIONS | MERCK & CO., INC. | 2001-02-27 | — | — | US | disclosed |
| WO-2000025774-A1 | BENZAMIDE POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190047977-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | KMO, KYNU, AADAT | PARP1 1696/4885NOTUM 527/4885AHR 57/4885 |
| US-20110165120-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, PRSS3, PRSS2 | PARP1 2912/4885NOTUM 1022/4885AHR 4212/4885 |
| US-10442782-B2 | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | KMO, KYNU, AADAT | PARP1 1696/4885NOTUM 527/4885AHR 57/4885 |
| US-20070179167-A1 | Inhibitors of serine proteases | PRSS1, PRSS3, PRSS2 | PARP1 2912/4885NOTUM 1022/4885AHR 4212/4885 |
| US-20180222838-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | KMO, KYNU, AADAT | PARP1 1696/4885NOTUM 527/4885AHR 57/4885 |
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, SPINT2, PRSS2 | PARP1 2904/4885NOTUM 1295/4885AHR 4284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.